Loxapine low dose inhalation - Alexza Pharmaceuticals

Drug Profile

Loxapine low dose inhalation - Alexza Pharmaceuticals

Alternative Names: AZ-104; Staccato loxapine low dose

Latest Information Update: 30 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexza Pharmaceuticals
  • Class Antipsychotics; Dibenzoxazepines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Migraine

Most Recent Events

  • 14 Sep 2009 The primary endpoint was not met in efficacy data from a phase IIb trial in Migraine released by Alexza
  • 11 Sep 2009 Suspended - Phase-II for Migraine in USA (Inhalation)
  • 30 Jun 2009 Alexza completes enrolment in its phase IIb trial for Migraine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top